scholarly journals Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Philippe Thuillier ◽  
David Bourhis ◽  
Jean Philippe Metges ◽  
Romain Le Pennec ◽  
Karim Amrane ◽  
...  

AbstractTo present the feasibility of a dynamic whole-body (DWB) 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors (WD-NETs). Sixty-one patients who underwent a DWB 68Ga-DOTATOC-PET/CT for a histologically proven/highly suspected WD-NET were prospectively included. The acquisition consisted in single-bed dynamic acquisition centered on the heart, followed by the DWB and static acquisitions. For liver, spleen and tumor (1–5/patient), Ki values (in ml/min/100 ml) were calculated according to Patlak's analysis and tumor-to-liver (TLR-Ki) and tumor-to-spleen ratios (TSR-Ki) were recorded. Ki-based parameters were compared to static parameters (SUVmax/SUVmean, TLR/TSRmean, according to liver/spleen SUVmean), in the whole-cohort and according to the PET system (analog/digital). A correlation analysis between SUVmean/Ki was performed using linear and non-linear regressions. Ki-liver was not influenced by the PET system used, unlike SUVmax/SUVmean. The regression analysis showed a non-linear relation between Ki/SUVmean (R2 = 0.55,0.68 and 0.71 for liver, spleen and tumor uptake, respectively) and a linear relation between TLRmean/TLR-Ki (R2 = 0.75). These results were not affected by the PET system, on the contrary of the relation between TSRmean/TSR-Ki (R2 = 0.94 and 0.73 using linear and non-linear regressions in digital and analog systems, respectively). Our study is the first showing the feasibility of a DWB 68Ga-DOTATOC-PET/CT acquisition in WD-NETs.

2021 ◽  
pp. jnumed.121.262652
Author(s):  
Philippe THUILLIER ◽  
Virginia LIBERINI ◽  
Serena GRIMALDI ◽  
Osvaldo RAMPADO ◽  
Elena GALLIO ◽  
...  

2011 ◽  
Vol 11 (1A) ◽  
pp. S38-S39 ◽  
Author(s):  
C. Pfannenberg ◽  
C. Schraml ◽  
N. Schwenzer ◽  
M. Werner ◽  
M. Muller ◽  
...  

2016 ◽  
Vol 122 (1) ◽  
pp. 43-50 ◽  
Author(s):  
Lina Carlbom ◽  
José Caballero-Corbalán ◽  
Dan Granberg ◽  
Jens Sörensen ◽  
Barbro Eriksson ◽  
...  

2017 ◽  
Vol 42 (9) ◽  
pp. 669-674 ◽  
Author(s):  
Dominik Berzaczy ◽  
Chiara Giraudo ◽  
Alexander R. Haug ◽  
Markus Raderer ◽  
Daniela Senn ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Quetzali Pitalua-Cortes ◽  
Francisco Osvaldo García-Perez ◽  
Joel Vargas-Ahumada ◽  
Sofia Gonzalez-Rueda ◽  
Edgar Gomez-Argumosa ◽  
...  

IntroductionThyroid cancer is the main endocrine neoplasia worldwide, for which 131I therapy is the cornerstone treatment. One of the main problems of follow up in patients with this type of cancer, is the need for thyroglobulin stimulation, not to mention the poor availability of 123I or 124I, to perform studies with a higher degree of sensitivity. Prostatic Specific Membrane Antigen (PSMA) PET/CT has demonstrated to be quite useful in a diversified number of neoplasms, on behalf of its capacity of evaluating the extent of type II carboxypeptidase expression in vascular endothelium. The end point of this article is to assess whether this novel image method possesses applicability in thyroid neoplasms follow up, for diagnostic and potentially therapeutic purposes.MethodsWe retrospectively evaluated well differentiated metastatic thyroid cancer patients, who underwent a post therapeutic 131I dose whole body scan (WBS) and complementary SPECT/CT, as well as 68Ga-PSMA–11 PET/CT.ResultsTen patients with differentiated thyroid cancer were included, of whom 80% were women and 20% men, mean age was 58 years old (± 11.6). Sixty-four metastatic lesions were analyzed, 67.19% had papillary histology and 32.81% were follicular type, the most affected site of metastases was bone in 57.81%, followed by lung 17.19%, lymph nodes 7.81%, postoperative thyroid bed 4.69%, brain 4.69% and others 7.81%. 68Ga PSMA-11 PET/CT detected 64/64 lesions, all of them also identified by computed tomography (CT), whereas 131I SPECT/CT detected 55/64 lesions. Discrepant lesions were localized in lung 44.4%, brain 22.2%, postoperative thyroid bed 11.1%, lymph nodes 11.1% and bone 11.1%. The degree of correspondence among observers was outstanding for both radiotracers, but close upon perfect for PSMA-11 (κ = 0.98; 95% CI, 0.80 – 0.91), as opposed to 131 I (κ = 0.86; 95% CI, 0.71 – 0.76).Conclusions68Ga-PSMA PET/CT showed an utterly superior capability for metastatic lesion detection when compared to 131I SPECT/CT. These findings suggest that PSMA PET/CT could possibly and precociously identify radioiodine refractoriness. PSMA uptake values not only expedite diagnosis, but also award it the ability to be used for therapeutic intents.


2015 ◽  
Vol 148 (4) ◽  
pp. S-935
Author(s):  
Margot Bucau ◽  
Astrid Laurent-Bellue ◽  
Jerome Cros ◽  
Olivia Hentic-Dhomé ◽  
Pierre Bedossa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document